



## (51) International Patent Classification:

A61K 31/381 (2006.01) A61K 9/00 (2006.01)  
A61K 31/5575 (2006.01)

## (21) International Application Number:

PCT/US2014/033558

## (22) International Filing Date:

9 April 2014 (09.04.2014)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/811,682 12 April 2013 (12.04.2013) US

## (71) Applicant: ALLERGAN, INC. [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

## (72) Inventors: WHITCUP, Scott M.; 27591 Lost Trail Drive, Laguna Hills, California 92653 (US). WOODWARD, David F., HUGHES, Patrick M.; 34 Fawnridge Place, Aliso Viejo, California 92656 (US).

## (74) Agents: WURST, John E. et al.; 2525 Dupont Drive, Irvine, California 92612 (US).

## (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

## Published:

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SUSTAINED RELEASE OF BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION

FIGURE 1



(57) Abstract: The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.

**SUSTAINED RELEASE OF BIMATOPROST, BIMATOPROST ANALOGS,  
PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION**

**CROSS REFERENCE TO RELATED APPLICATION**

This application claims the benefit of United States Provisional Patent Application Serial No. 61/811,682, filed April 12, 2013, the entire disclosure of which is incorporated herein by reference.

**SUMMARY OF THE INVENTION**

The present invention is directed to compositions and methods for the sustained release of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs and prostaglandin derivatives from injectable and implantable depots for the purpose of fat reduction including localized fat reduction.

Topical bimatoprost has been shown to effectively prevent adipocyte formation and maturation and to atrophy adipocytes in animal models after topical administration. Furthermore, clinical evidence of fat reduction after topical administration of bimatoprost has been reported. The present invention is directed to sustained release methods and formulations of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs and derivatives and prostaglandin analogs such as latanoprost and travoprost for localized fat reduction.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows *in vitro* release profiles of bimatoprost with injectable PLGA implants;

Figure 2 shows *in vitro* release profiles of bimatoprost with injectable SynBiosys implants;

Figures 3A and 3B show 100 day ReGel 100 or ReGel B release data;

Figures 4A – 4C show a comparison of latanoprost release data of ReGel 100 or ReGel B delivery systems;

Figure 5 shows a 2-D MR image 40 minutes post-injection oriented longitudinal through the gastrocnemius muscle to show the MGL and MGM muscle groups in each leg. The right leg was injected with HA/Albumin-Gadolinium, the left leg with Albumin-Gadolinium alone;

Figure 6A shows the release rate of bimatoprost in a formulation of 20% Bimatoprost, 45% R203s, 20% RG752s 10% R202H, 5% PEG-3350;

Figure 6B shows the release rate of bimatoprost in a formulation shown at the bottom of Figure 6B;

Figure 6C shows the release rate of Compound #1 of the formulations of Table I;

Figure 7A shows bimatoprost microspheres which can be used for sustained release of bimatoprost for localized fat reduction;

Figure 7B shows the release rate of bimatoprost from the latanoprost microspheres;

- 5 Figures 8A and 8B show shows 10% bimatoprost in diethyl glycol dibenzoate (gel); and,  
Figure 8C shows an example of bimatoprost release from a 10% Bimatoprost in Diethyl Glycol Dibenzoate depot (gel).

Some embodiments of the invention are included in the following paragraphs:

- 10
- 1) A method of fat reduction comprising injecting a sustained release formulation of a compound selected from the group consisting of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs, latanoprost and travoprost and prostaglandin derivatives and mixtures thereof into a fat deposit.
  - 15
  - 2) The method of paragraph 1 wherein the compound is selected from the group consisting of bimatoprost, latanoprost, travoprost and Compound # 1 and mixtures thereof.
  - 3) The method of paragraph 1 wherein the sustained release formulation is selected from the group consisting of injectable depots, gel suspensions, a ReGel delivery system, a hyaluronic acid release platform, implants, microspheres, macrospheres and injectable solvents.
  - 20
  - 4) The method of paragraphs 2 or 3 wherein the compound is bimatoprost.
  - 25
  - 5) The method of paragraphs 1 - 4 wherein the sustained release formulation is injected directly into the fat deposit.
  - 6) The method of paragraph 1 wherein the fat reduction is localized fat reduction at and around the injection site.
  - 30
  - 7) The method of paragraphs 1 or 3 wherein the sustained release formulation is an implant with the formulation of about 20% bimatoprost, about 45% R203s, about 20% RG752s, about 10% R202H and about 5% PEG-3350.

- 8) The method of paragraphs 1 or 3 wherein the method results in atrophy of both brown and white adipocytes and results in localized fat reduction.
- 9) The method of paragraph 7 wherein the implant releases bimatoprost in the fat deposit for over a  
5 period of 100 days.
- 10) The method of paragraph 1 wherein the sustained release formulation releases the compound systemically to target a fat deposit at a location in the body that is not at the location of the sustained released formulation or at difficult to reach areas.
- 10 11) The method of paragraphs 1 or 10 wherein the sustained release formulations are injected or implanted at a location that permits reduction of abdominal fat deposits, visceral fat deposits, epicardial fat deposits, subcutaneous fat deposits and ectopic fat deposits as non-limiting examples.
- 15 12) A composition for use in localized fat reduction wherein the composition is a sustained release composition selected from the group consisting of injectable depots, gel suspensions, a ReGel delivery system, a hyaluronic acid based platform, implants, microspheres, macrospheres and injectable solvents.
- 20 13) The composition of paragraph 12 wherein the composition further comprises a compound selected from the group consisting of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs, latanoprost and travoprost and prostaglandin derivatives.
- 14) The composition of paragraph 12 and 13 wherein the sustained release composition is a Regel  
25 delivery system and the compound is bimatoprost.
- 15) The composition of paragraph 14 wherein the composition is injected into a localized fat deposit.
- 16) The composition of paragraph 15 wherein the composition is injected at multiple injection sites into a  
30 single localized fat deposit.
- 17) The composition of paragraph 15 wherein the composition releases bimatoprost into the localized fat deposit for over a period of 100 days.

- 18) The composition of paragraph 12 or 13 wherein the sustained release formulation is an implant comprised of about 20% bimatoprost, about 45% R203s, about 20% RG752s, about 10% R202H and about 5% PEG-3350.
- 5 19) The composition of paragraph 18 wherein the composition is injected into at least one selected from the group consisting of abdominal fat deposits, visceral fat deposits, epicardial fat deposits, subcutaneous fat deposits and ectopic fat deposits.
- 10 20) The composition of paragraph 18 wherein injection of the composition results in atrophy of adipocytes in the localized fat deposit and reduction of localized fat.
- 15 21) The composition of paragraph 12 or 13 wherein the sustained release formulation is an implant comprised of at least one polymer selected from the group consisting of poly(d,l-lactide-co-glycolide), poly(d,l-lactide), poly(caprolactone), poly(dioxanone), poly(ethylene glycol), poly(ortho-ester), polyesters, poly(phosphazine), poly(phosphate ester), polycaprolactone, silicone, natural polymers such as latex, gelatin or collagen, or polymeric blends and the compound is selected from the group consisting of bimatoprost, latanoprost, travoprost and mixtures thereof.
- 20 22) The composition of paragraph 12 or 13 wherein the sustained release formulation is a gel suspension comprised of at least one compound selected from the group consisting of sodium hyaluronate, crosslinked hyaluronic acid, chondroitin sulfate, cellulose, gelatin, collagen, glycosaminoglycans, or other synthetic or naturally occurring polysaccharides and the compound is selected from the group consisting bimatoprost, latanoprost, travoprost and mixtures thereof.
- 25 23) The composition of paragraph 22 wherein the gel suspension is a thermal gelling delivery system.
- 24) The composition of paragraph 22 wherein the thermal gelling system is comprised of solutions of A-B-A or B-A-B triblock copolymers or B-A block copolymers.
- 30 25) The composition of paragraph 12 or 13 wherein the sustained release formulation is an injectable depot with biocompatible solvents selected from the group consisting of DMSO, NMP and DMAC or mixtures thereof.

**DETAILED DESCRIPTION OF THE INVENTION**

Bimatoprost and other compounds can be dissolved or dispersed in a gel, in a biodegradable solid implant, or biocompatible solvents containing solvated polymers, which can form solid depots upon injection. Additionally, thermal gelling delivery systems of bimatoprost may also be utilized. Solid implants for sustained release may be comprised of poly(d,l-lactide-co-glycolide), poly (d,l-lactide), poly(caprolactone), poly(dioxanone), poly(ethylene glycol), poly(ortho-ester), polyesters, poly(phosphazine), poly (phosphate ester), polycaprolactone, silicone, natural polymers such as latex, gelatin or collagen, or polymeric blends. Gel suspensions could contain sodium hyaluronate, crosslinked hyaluronic acid, chondroitin sulfate, cellulose, gelatin, collagen, glycosaminoglycans, or other synthetic or naturally occurring polysaccharides. Biocompatible solvents for injection of in situ forming depots include DMSO (dimethyl sulfoxide), NMP (N-methylpyrrolidone), DMAC (dimethylacetamide), or other non-aqueous solvents for injection.

Bimatoprost delivery systems and delivery systems for other compounds can be administered for reduction of adipose tissue through the injection or implantation of implants or injectable depots. Such delivery systems may be used for reduction of local adipose tissue, e.g subcutaneous fat, and/or as a method for sustained systemic delivery to achieve reduction of visceral fat and other fat pad depositions that are not easily reached by local administration of the implant or injection such as pericardial fat depositions. . Bimatoprost is a low melting compound and the ability to sustain its release from multiple delivery platforms is surprising. Specific delivery platforms include but are not limited to injectable bimatoprost delivery depots, in situ forming bimatoprost depots, hyaluronic acid depots, solid form bimatoprost implants, bimatoprost microspheres and injectable solvent depots.

The delivery systems of the present invention can be injected or implanted at a location to achieve reduction of subcutaneous fat deposits and adipose tissue such as abdominal fat, visceral fat, epicardial fat, submental fat, periorbital fat and ectopic fat pads.

**Example I****Injectable Depots**

PLGA and multiblock polymers have been shown to release bimatoprost upon depot formation. The polymers and drug are dissolved in a biocompatible solvent for both, such as N-methylpyrrolidinone, di-methyl acetamide or DMSO. The formulation is sterile filtered, autoclaved, or irradiated for sterility.

The solution is filled into a sterile vial or a unit dose syringe. After injection, the biocompatible solvent diffuses away from the depot, leaving behind a firm prostamide or prostaglandin loaded implant. The depot releases bimatoprost, prostamide or prostaglandin for days, weeks, or months, as the polymer bioerodes. Drug loading in solution could range from 0.1% to 50%. Polymer loading in solution could range from 15% to 50%. Excipients could include poly(ethylene glycol), short chain fatty acids, waxes, cholesterol, aliphatic alcohols, co-solvents, or other compounds which would adjust the hydrophobicity of the depot.

With both PLGA and SynBiosys bimatoprost containing injectable depots, the drug was continuously released for at least one month as shown in figures 1 and 2. It is possible to further optimize the release kinetics by varying drug load, polymer concentration, polymer properties, formulation excipients or DMSO volume used for implant preparation.

### **Example II**

#### **ReGel Delivery System**

Polymer systems that undergo phase transitions in response to various stimuli can also be used. This phase transition results in a significant volume and or viscosity change in the system. The system can respond to pH, ionic environment, temperature, biologic triggers as well as other chemical and physical triggers. The system comprises one or more polymers capable of interacting to cause a phase-transition resulting in the volume or viscosity increases. Examples of polymers include polyacrylic acid and polyethylene oxide copolymers. Other components of the system include excipients known to those experienced in the art.

The system has the further advantage of offering controlled and sustained release of therapeutically active agents to local tissues. The drug may be physically entrapped or chemically bound via covalent linkages, hydrogen binding, ionic interactions, van der Waals forces or hydrophobic interactions. Release of the drug can be controlled by physical entrapment of the active compound in the transitioned gel. Compounds can also be physically or chemically bound to the polymers comprising the phase transition gel. The phase transition of the gel serves to create a depot for drug delivery.

A specific example of this invention teaches the use of thermal gelling bimatoprost delivery systems comprised of solutions of A-B-A or B-A-B triblock copolymers or B-A block

copolymers where A = polylactide-co-glycolide (PLGA/ PLA) and B = polyethylene oxide (PEO) and latanoprost. These polymers make up the Regel in situ gelling delivery system. Its aqueous solutions have shown to have sol-to-gel transition behavior as temperature increases. For drug delivery applications, gelation at physiologically relevant temperature (e.g., 37°C) is particularly important and forms the basis for the utility of the systems for medical and drug delivery purposes.

In the specific example, latanoprost was loaded at 3% loading into ReGel 100 or ReGel B i.e. 3 mg drug in 100ul gel. The system displayed sustained release after thermal gelation with no burst of latanoprost. This is very surprising given the relative low melting point and solubility of latanoprost. i.e., slow release, no burst. The gel remained for longer than 100 days as shown in Figures 3A and 3B. Additional modifications can be made by adding other polymers to the system, e.g., CMC, agarose and starch.

### **Example III**

#### **Hyaluronic Acids**

Crosslinked hyaluronic acid has been shown to localize upon injection providing a potential sustained release platform. Drug can either be incorporated into the crosslinked hyaluronic acid or conjugated to the vehicle for sustained release. In the case of the former, release and erosion of the platform can be controlled by porosity of the gel, length of the crosslinkers and crosslinking density. Alternatively, in the latter case, bimatoprost or a prostamide analog can be covalently or ionically bonded to the hyaluronic backbone through one of several linkers known to the art. Finally, drug may be incorporated into another sustained release modality, such as microspheres, then incorporated into the hyaluronic acid (crosslinked or non-crosslinked) and injected as a delivery platform.

Figure 5 shows a 2-D MR image 40 minutes post-injection oriented longitudinal through the gastrocnemius muscle to show the MGL (tripennate gastrocnemius lateralis) and MGM (unipennate gastrocnemius medialis) muscle groups in each leg. The right leg was injected with HA/Albumin-Gadolinium, the left leg with Albumin-Gadolinium alone. The left leg shows diffuse spread of the Albumin-Gadolinium (blue color) throughout the MGL muscle and crossover to the adjacent MGM muscle. This data shows that cross-linked HA depots can be localized and provide a platform for the local sustained release of a prostaglandin or prostamide for fat reduction.




**Example IV**

5

**Implants**

10 Bimatoprost has been formulated into implants that can be injected or implanted subcutaneously, into visceral fat or in direct apposition to an organ. An example is the following formulation : 20% Bimatoprost, 45% R203s, 20% RG752s, 10% R202H, 5% PEG-3350 and Figure 6A shows the release rate of bimatoprost from this formulation (R203S is an ester end-capped PLA, R202H is an acid end group PLA, RG752S is a 75:25 PLGA with an ester end group and PEG\_3350 is polyethylene glycol with a molecular weight of 3350). Other implant formulations and their release rates are shown in Fig 6B.

15 Another compound (Compound #1) which may be useful for fat reduction is disclosed below:



20 Implant formulations with Compound #1 and their properties are in Table I below:

Examples	Lot #	compositions	implant dimension	implant wt (μg)	in vitro release rate (μg/d)	estimated release duration (month)
1	10524-101	8.0% API, 92.0% R202H	150μm x 1.5 mm	36	29	3
2	10810-061	8.0% API, 92.0% R203H	200μm x 1.5 mm	64	26	6
3	10810-080	8.0% API, 51.7% R203S, 23.0% RG752S, 11.5%	200μm x 1.5 mm	64	34	4-5

		R202H, 5.8% hexadecanol				
4	10810-116	8.0% API, 18.4% R203S, 73.6% R203H	200µm x 1.5 mm	64	28	6

### Example V

#### Microspheres

5 Bimatoprost and latanoprost can also be sustained through the use of PLGA microspheres and  
 macrospheres as shown in Figures 7A -7B for latanoprost. Latanoprost microspheres were manufactured  
 from the PLA and PLGA polymers as shown in the table below. The microspheres were manufactured by  
 dissolving 20 mg of latanoprost and 100 mg polymer in 0.8 ml ethyl acetate. A minimum amount of  
 dichloromethane may be added to complete dissolution of the polymer. This solution is added to 40 mL  
 10 1% polyvinyl alcohol aqueous solution via a micro-pipette while mixing at high shear, 3000 rpm, for 5  
 minutes with a homogenizer.

After shearing, a milky white emulsion is formed, and it is mildly agitated in a fume hood for 3-5  
 hours to allow solvent evaporation. This dispersion is then centrifuged at 2000 rpm for 15 min to remove  
 15 supernatant, and then 10 mL water is added to reconstitute the microspheres. The final reconstituted  
 micropsheres are lyophilized. The release of latanoprost from the microspheres into isotonic phosphate  
 buffered saline is shown in Figure 7B

Lot number	Polymer	drug load %	entrap efficiency %	PS before freeze drying, µm		
				d10	d90	Mean
MP-5	203H	13.5%	81.0%	15.4	59.2	31.9
MP-8	R203S	12.2%	73.3%	15.8	64.5	34.7
MP-11	RG755	11.9%	71.3%	17.4	66.3	35.6

20

### Example VI

#### Injectable solvents

Other excipients such as sucrose acetate isobutyrate, ethyl benzoate, benzyl benzoate, tripropionin, diethyl Glycol dibenzoate among others can be used for direct injection subcutaneously or into the fat. Figures 8A- 8B shows 10% bimatoprost in Diethyl Glycol Dibenzoate (gel) and Figure 8C shows an example of bimatoprost release from 10% Bimatoprost in Diethyl Glycol Dibenzoate (gel).

**CLAIMS**

- 1) A method of fat reduction comprising injecting a sustained release formulation of a compound selected from the group consisting of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs, latanoprost and travoprost and prostaglandin derivatives and mixtures thereof into a fat deposit.  
5
- 2) The method of claim 1, wherein the compound is selected from the group consisting of bimatoprost, latanoprost, travoprost and Compound # 1 and mixtures thereof.  
10
- 3) The method of claim 1, wherein the sustained release formulation is selected from the group consisting of injectable depots, gel suspensions, a ReGel delivery system, a hyaluronic acid release platform, implants, microspheres, macrospheres and injectable solvents.
- 15 4) The method of claim 3, wherein the compound is bimatoprost.
- 5) The method of claim 1, wherein the sustained release formulation is injected directly into the fat deposit.
- 20 6) The method of claim 1, wherein the fat reduction is localized fat reduction at and around the injection site.
- 7) The method of claim 3, wherein the sustained release formulation is an implant with the formulation of about 20% bimatoprost, about 45% R203s, about 20% RG752s, about 10% R202H and about 5%  
25 PEG-3350.
- 8) The method of claim 1, wherein the method results in atrophy of both brown and white adipocytes and results in localized fat reduction.
- 30 9) The method of claim 7, wherein the implant releases bimatoprost in the fat deposit for over a period of 100 days.
- 10) The method of claim 1, wherein the sustained release formulation releases the compound systemically to target a fat deposit at a location in the body that is not at the location of the sustained release  
35 formulation.

- 11) The method of claims 1 or 10, wherein the sustained release formulations are injected or implanted at a location that permits reduction of abdominal fat deposits, visceral fat deposits, epicardial fat deposits, subcutaneous fat deposits and ectopic fat deposits.
- 5
- 12) A composition for use in localized fat reduction wherein the composition is a sustained release composition selected from the group consisting of injectable depots, gel suspensions, a ReGel delivery system, a hyaluronic acid based platform, implants, microspheres, macrospheres and injectable solvents.
- 10
- 13) The composition of claim 12, wherein the composition further comprises a compound selected from the group consisting of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs, latanoprost and travoprost and prostaglandin derivatives.
- 15
- 14) The composition of claim 12, wherein the sustained release composition is a ReGel delivery system and the compound is bimatoprost.
- 15) The composition of claim 14, wherein the composition is injected into a localized fat deposit.
- 20
- 16) The composition of claim 15, wherein the composition is injected at multiple injection sites into a single localized fat deposit.
- 17) The composition of claim 15, wherein the composition releases bimatoprost into the localized fat deposit for over a period of 100 days.
- 25
- 18) The composition of claim 12 or 13, wherein the sustained release formulation is an implant comprised of about 20% bimatoprost, about 45% R203s, about 20% RG752s, about 10% R202H and about 5% PEG-3350.
- 30
- 19) The composition of claim 18, wherein the composition is injected into at least one selected from the group consisting of abdominal fat deposits, visceral fat deposits, epicardial fat deposits, subcutaneous fat deposits and ectopic fat deposits.

- 20) The composition of claim 18, wherein injection of the composition results in atrophy of adipocytes in the localized fat deposit and reduction of localized fat.

1/10

FIGURE 1





FIGURE 2





3/10

FIGURE 3A







FIGURE 3B



4/10

**Figure 4A****Figure 4B**

5/10

Figure 4C





Figure 5



7/10

Figure 6A






Figure 6B



8/10

Figure 6 C



9/10

Fig. 7A





Fig 7B



10/10

Fig.8A




Fig. 8B





Fig. 8 C





## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2014/033558

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K31/381 A61K31/5575 A61K9/00  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2007/111806 A2 (MASSACHUSETTS EYE & EAR INFIRM [US]; GROSSKREUTZ CYNTHIA L [US]; PASQU) 4 October 2007 (2007-10-04)	1-6,8, 10-17
Y	paragraph [0014] paragraphs [0029] - [0031] paragraph [0073] examples 1-8  -----  -/--	1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 July 2014

Date of mailing of the international search report

29/08/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Loher, Florian

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/033558

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>HEE YOUNG CHOI ET AL: "In Vitro Study of Antiadipogenic Profile of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in Human Orbital Preadipocytes", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS., vol. 28, no. 2, 1 April 2012 (2012-04-01), pages 146-152, XP055131156, US  ISSN: 1080-7683, DOI: 10.1089/jop.2011.0160  page 150 - page 151</p> <p>-----</p>	1-20
Y	<p>WO 2011/109384 A2 (ALLERGAN INC [US]; ROBINSON MICHAEL R [US]; LEE SUSAN S [US]; WHITCUP) 9 September 2011 (2011-09-09)  claim 1; example 4</p> <p>-----</p>	1-20
Y	<p>WO 2008/070402 A2 (ALLERGAN INC [US]; ROBINSON MICHAEL R [US]; BLANDA WENDY M [US]; HUGHE) 12 June 2008 (2008-06-12)  examples 1-3</p> <p>-----</p>	1-20

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/033558

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007111806 A2	04-10-2007	CA 2681668 A1	04-10-2007
		US 2008015257 A1	17-01-2008
		US 2010234466 A1	16-09-2010
		US 2014163098 A1	12-06-2014
		WO 2007111806 A2	04-10-2007
WO 2011109384 A2	09-09-2011	US 2013071349 A1	21-03-2013
		WO 2011109384 A2	09-09-2011
WO 2008070402 A2	12-06-2008	AR 064078 A1	11-03-2009
		AU 2007329723 A1	12-06-2008
		CA 2670746 A1	12-06-2008
		CN 101588770 A	25-11-2009
		CN 102512356 A	27-06-2012
		CN 103893106 A	02-07-2014
		EP 2099387 A2	16-09-2009
		EP 2218424 A1	18-08-2010
		IL 198804 A	31-03-2014
		JP 5419703 B2	19-02-2014
		JP 2010511433 A	15-04-2010
		KR 20090085154 A	06-08-2009
		NZ 577105 A	26-10-2012
		NZ 600921 A	30-05-2014
		RU 2009122647 A	10-01-2011
		TW 200826943 A	01-07-2008
		US 2008131484 A1	05-06-2008
		WO 2008070402 A2	12-06-2008